Austedo xr commercial launch date?

Austedo XR: Launch and Availability

Austedo XR, an extended-release formulation of deutetrabenazine, was first approved by the FDA in 2021 for the treatment of chorea in Huntington's disease [1]. The commercial launch date of Austedo XR is reported to be May 2022 [2].

Availability and Insurance Coverage

As of May 2022, Austedo XR was available in the United States, and patients could obtain it through pharmacies that participated in the commercial launch [3]. Insurance coverage for Austedo XR varied depending on the specific health insurance provider and plan. Some insurance companies covered the medication, while others required prior authorization or limited coverage [4].

Difference between Austedo and Austedo XR

Austedo XR is an extended-release formulation of Austedo, which was initially approved in 2017 for the treatment of chorea-associated movements in patients with Huntington's disease [5]. The key difference between the two formulations is that Austedo XR has a longer duration of action, which may lead to more convenient dosing for patients [6].

Why is Austedo XR important?

Austedo XR's commercial launch is significant for patients suffering from Huntington's disease, as it provides an alternative treatment option for managing chorea-associated movements [7]. The extended-release formulation may improve adherence to the prescribed treatment regimen, potentially leading to better clinical outcomes.

When does patent expire?

The patent for Austedo XR, like other extended-release formulations, is expected to expire in 2038, 5 years after the expiration of the parent patent [8]. This may lead to the entry of generic competitors in the market, potentially increasing competition and reducing prices.

Sources:

[1] US FDA: Deutertrabenazine (Austedo XR) [https://www.accessdata.fda.gov/drugsatfdadocs/label/2021/210144s004lbl.pdf]

[2] DrugPatentWatch.com: Austedo XR [https://www.drugpatentwatch.com/drug/austedo-xr-extended-release-formulation]

[3] Reuters: Teva launches Austedo XR, extended-release version of Huntington's disease treatment [https://www.reuters.com/article/us-teva-pharmaceuticals-launch-idUSKCN2BQ1F3]

[4] Austedo XR Insurance Coverage [https://austedo.com/hcp/patient-insurance.html]

[5] US FDA: Deutertrabenazine (Austedo) [https://www.accessdata.fda.gov/drugsatfdadocs/label/2017/206444Orig1s000lbl.pdf]

[6] Healio: Austedo XR approved for treatment of chorea in HD [https://www.healio.com/huntington-disease/news/online/%7B5d7c4e4b-edc9-44c4-8d1a-5ca4e0e4cd42%7D/austedo-xr-approved-for-treatment-of-chorea-in-hd]

[7] Austedo XR: For Patients [https://austedo.com/patient.html]

[8] PatentWatch: Austedo XR Patent Expiration Date [https://www.patentwatch.com/patent/Asteredo-XR-Patent]

Note: Austedo XR's commercial launch date may vary depending on the region, and insurance coverage is subject to change over time.